Shiho Kuji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shiho Kuji has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Nao Suzuki
Department of Obstetrics and Gynecology, St. Marianna Medical University School of Medicine, Kawasaki, Japan
7 shared publications Yasuyuki Hirashima
Division of gynecology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
5 shared publications- Hiroaki Kajiyama
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
4 shared publications Aki Tanaka
Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Shizuoka, Japan
3 shared publications- Allen Gideon Tan
Department of Obstetrics and Gynecology, University of the Philippines Manila, Manila, Philippines
3 shared publications - Angela Cho
Department of Obstetrics and Gynecology, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Current status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessCurrent status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Current status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessCurrent status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
The real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions
Yoshihara M, et al. J Gynecol Oncol. 2027 ;38:e17. https://doi.org/10.3802/jgo.2027.38.e17
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessThe real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions
Yoshihara M, et al. J Gynecol Oncol. 2027 ;38:e17. https://doi.org/10.3802/jgo.2027.38.e17
- 9 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
Integrated host vulnerability assessment using prognostic nutritional index and psoas muscle index for predicting chemotherapy-related toxicity in ovarian cancer: a multicenter JGOG9005S cohort analysis
Objective: To evaluate associations of prechemotherapy prognostic nutritional index (PNI) and computed tomography (CT)-derived muscle measures with severe chemotherapy-related toxicity in ovarian cancer and explore their combined assessment. Methods: This multicenter retrospective cohort included 109 patients treated with platinum-taxane chemotherapy. PNI was calculated from laboratory values obtained immediately before the first chemotherapy cycle, irrespective of treatment sequence. Psoas muscle index (PMI) was measured centrally on baseline CT images. Associations with grade ≥ 3 chemotherapy-related adverse events were estimated using separate age- and stage-adjusted logistic models. Discrimination was compared among nested models in the same complete-case cohort. Cutoff-based and treatment-sequence analyses were exploratory. Results: Grade ≥ 3 toxicity occurred in 63 patients (57.8%). Higher PNI and PMI were associated with lower odds of severe toxicity (adjusted odds ratios, 0.966 per PNI unit; 95% CI, 0.935–0.994; P = 0.024; and 0.598 per cm2/m2; 0.379–0.899; P = 0.018, respectively). The combined PNI-PMI model showed numerically improved discrimination compared with individual parameters (area under the curve, 0.694). In exploratory cohort-defined groups, toxicity occurred in 36.4%, 58.3%, and 75.7% of patients with zero, one, and two vulnerability domains, respectively; the adjusted odds ratio was 2.38 per domain (95% CI, 1.41–4.20, P = 0.0018). Conclusions: Lower prechemotherapy PNI and lower baseline PMI were associated with severe chemotherapy-related toxicity. The combined model showed modest discrimination, and cohort-derived classifications require prospective external validation before clinical implementation.
- 9 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
Integrated host vulnerability assessment using prognostic nutritional index and psoas muscle index for predicting chemotherapy-related toxicity in ovarian cancer: a multicenter JGOG9005S cohort analysis
Objective: To evaluate associations of prechemotherapy prognostic nutritional index (PNI) and computed tomography (CT)-derived muscle measures with severe chemotherapy-related toxicity in ovarian cancer and explore their combined assessment. Methods: This multicenter retrospective cohort included 109 patients treated with platinum-taxane chemotherapy. PNI was calculated from laboratory values obtained immediately before the first chemotherapy cycle, irrespective of treatment sequence. Psoas muscle index (PMI) was measured centrally on baseline CT images. Associations with grade ≥ 3 chemotherapy-related adverse events were estimated using separate age- and stage-adjusted logistic models. Discrimination was compared among nested models in the same complete-case cohort. Cutoff-based and treatment-sequence analyses were exploratory. Results: Grade ≥ 3 toxicity occurred in 63 patients (57.8%). Higher PNI and PMI were associated with lower odds of severe toxicity (adjusted odds ratios, 0.966 per PNI unit; 95% CI, 0.935–0.994; P = 0.024; and 0.598 per cm2/m2; 0.379–0.899; P = 0.018, respectively). The combined PNI-PMI model showed numerically improved discrimination compared with individual parameters (area under the curve, 0.694). In exploratory cohort-defined groups, toxicity occurred in 36.4%, 58.3%, and 75.7% of patients with zero, one, and two vulnerability domains, respectively; the adjusted odds ratio was 2.38 per domain (95% CI, 1.41–4.20, P = 0.0018). Conclusions: Lower prechemotherapy PNI and lower baseline PMI were associated with severe chemotherapy-related toxicity. The combined model showed modest discrimination, and cohort-derived classifications require prospective external validation before clinical implementation.
- 18 October 2023
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (1) , 75-85
Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy
Objective: Gynecologic cancer chemotherapy impacts the quality of life (QOL) of patients, with lasting adverse events that may require treatment adjustments or discontinuation. Consequently, real‐time symptom monitoring before outpatient visits has resulted in improved QOL for patients and extended survival times. This study investigated whether there are differences between electronic patient‐reported outcomes (e‐PRO‐CTCAE) and physician‐assessed outcomes (NCI‐CTCAE) evaluated in an outpatient setting in gynecologic cancer chemotherapy.Methods: The study was conducted on 50 patients who received their first chemotherapy treatment at St. Marianna University Hospital Obstetrics and Gynecology from July 1, 2021 to December 31, 2022. PRO‐CTCAE and NCI‐CTCAE were evaluated at each instance of chemotherapy and 2 weeks after. The PRO‐CTCAE was additionally collected weekly using e‐PRO.Results: The values for “Joint Pain,” “Nausea,” “Taste Disturbance,” “Constipation,” “Insomnia,” “Fatigue,” “Limb Edema,” and “Concentration Impairment” were consistently higher in PRO‐CTCAE than in NCI‐CTCAE, indicating that physicians underestimated the severity of adverse events. In contrast, there was no significant difference in “Peripheral Neuropathy,” demonstrating that physicians had a good understanding of this condition in patients. The weekly responses obtained from e‐PRO revealed that symptom exacerbations peaked outside of clinic visits.Conclusions: This study demonstrated physicians tend to underestimate most adverse events. Moreover, the responses using e‐PRO revealed peak symptom deterioration occurred outside of outpatient visits. This suggested that e‐PRO and actions taken in response to them can improve patients' QOL.
- 18 October 2023
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (1) , 75-85
Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy
Objective: Gynecologic cancer chemotherapy impacts the quality of life (QOL) of patients, with lasting adverse events that may require treatment adjustments or discontinuation. Consequently, real‐time symptom monitoring before outpatient visits has resulted in improved QOL for patients and extended survival times. This study investigated whether there are differences between electronic patient‐reported outcomes (e‐PRO‐CTCAE) and physician‐assessed outcomes (NCI‐CTCAE) evaluated in an outpatient setting in gynecologic cancer chemotherapy.Methods: The study was conducted on 50 patients who received their first chemotherapy treatment at St. Marianna University Hospital Obstetrics and Gynecology from July 1, 2021 to December 31, 2022. PRO‐CTCAE and NCI‐CTCAE were evaluated at each instance of chemotherapy and 2 weeks after. The PRO‐CTCAE was additionally collected weekly using e‐PRO.Results: The values for “Joint Pain,” “Nausea,” “Taste Disturbance,” “Constipation,” “Insomnia,” “Fatigue,” “Limb Edema,” and “Concentration Impairment” were consistently higher in PRO‐CTCAE than in NCI‐CTCAE, indicating that physicians underestimated the severity of adverse events. In contrast, there was no significant difference in “Peripheral Neuropathy,” demonstrating that physicians had a good understanding of this condition in patients. The weekly responses obtained from e‐PRO revealed that symptom exacerbations peaked outside of clinic visits.Conclusions: This study demonstrated physicians tend to underestimate most adverse events. Moreover, the responses using e‐PRO revealed peak symptom deterioration occurred outside of outpatient visits. This suggested that e‐PRO and actions taken in response to them can improve patients' QOL.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (1)
Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix
Kuji S, et al. J Gynecol Oncol. 2022 Oct;34(1):e1. https://doi.org/10.3802/jgo.2023.34.e1
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (1)
Open AccessImmunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix
Kuji S, et al. J Gynecol Oncol. 2022 Oct;34(1):e1. https://doi.org/10.3802/jgo.2023.34.e1
- 23 December 2021
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 48 (3) , 806-816
Survival and reproductive outcomes after fertility‐sparing surgery performed for borderline epithelial ovarian tumor in Japanese adolescents and young adults: Results of a retrospective nationwide study
Objective: Epithelial borderline ovarian tumor (BOT) frequently occurs in young women. Because progression‐free survival, overall survival, and reproductive function are important outcomes, BOT is often treated by fertility‐sparing surgery (FSS). We conducted a Japan‐wide study to understand post‐FSS prognosis in relation to clinical characteristics and types of FSS performed.Methods: We analyzed clinical and outcome data pertaining to 531 adolescent and young adult (AYA) patients (aged 15–39 years) who underwent FSS for BOT between 2009 and 2013.Results: Median (range) age was 30 (15–39) years, and median observation time was 70 (2–120) months. The disease was of FIGO stage I in 492 (93%) patients. Histopathologically, tumors were of the mucinous (n = 372, 70%), serous (n = 120, 23%), seromucinous (n = 23, 4%), and other (n = 16, 3%) types. Five‐year overall survival was 99.5% among patients with stage I and 100% among those with stage II–IV. Five‐year progression‐free survival was 96.7% and 69.3%, respectively. Multivariate analysis in cases of stage I showed a positive peritoneal cytology to be a significant risk factor for recurrence (HR, 5.199; p = 0.0188). The post‐FSS pregnancy rate was relatively low for patients aged ≥30 years (OR, 0.868; 95% CI, 1.16–3.00; p = 0.0090).Conclusion: Post‐FFS outcomes in terms of overall and progression‐free survival are favorable, especially for AYA patients with stage I BOT. However, the relapse rate is high for patients with FIGO stage II–IV and for those with stage I but a positive peritoneal cytology. A long‐term prospective observation is needed before reproductive outcomes can be fully established.
- 23 December 2021
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 48 (3) , 806-816
Survival and reproductive outcomes after fertility‐sparing surgery performed for borderline epithelial ovarian tumor in Japanese adolescents and young adults: Results of a retrospective nationwide study
Objective: Epithelial borderline ovarian tumor (BOT) frequently occurs in young women. Because progression‐free survival, overall survival, and reproductive function are important outcomes, BOT is often treated by fertility‐sparing surgery (FSS). We conducted a Japan‐wide study to understand post‐FSS prognosis in relation to clinical characteristics and types of FSS performed.Methods: We analyzed clinical and outcome data pertaining to 531 adolescent and young adult (AYA) patients (aged 15–39 years) who underwent FSS for BOT between 2009 and 2013.Results: Median (range) age was 30 (15–39) years, and median observation time was 70 (2–120) months. The disease was of FIGO stage I in 492 (93%) patients. Histopathologically, tumors were of the mucinous (n = 372, 70%), serous (n = 120, 23%), seromucinous (n = 23, 4%), and other (n = 16, 3%) types. Five‐year overall survival was 99.5% among patients with stage I and 100% among those with stage II–IV. Five‐year progression‐free survival was 96.7% and 69.3%, respectively. Multivariate analysis in cases of stage I showed a positive peritoneal cytology to be a significant risk factor for recurrence (HR, 5.199; p = 0.0188). The post‐FSS pregnancy rate was relatively low for patients aged ≥30 years (OR, 0.868; 95% CI, 1.16–3.00; p = 0.0090).Conclusion: Post‐FFS outcomes in terms of overall and progression‐free survival are favorable, especially for AYA patients with stage I BOT. However, the relapse rate is high for patients with FIGO stage II–IV and for those with stage I but a positive peritoneal cytology. A long‐term prospective observation is needed before reproductive outcomes can be fully established.
- 30 December 2020
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 51 (3) , 492-497
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report
BRCA1/2 mutation carriers are at high risk for type II ovarian, fallopian tube or peritoneal cancer. Although risk-reducing salpingo-oophorectomy plays an important role in the prevention of these BRCA1/2-associated gynecological cancers, occult ovarian, fallopian tube, or peritoneal cancer is discovered upon risk-reducing salpingo-oophorectomy in 1–4% of BRCA1/2 mutation carriers. Notably, around 30% of BRCA1/2 mutation carriers who undergo risk-reducing salpingo-oophorectomy have undergone adjuvant chemotherapy for breast cancer. We describe the discovery and treatment of occult cancer at the edge of the left fimbria in a BRCA1 mutation carrier who had, just a short time previously, undergone neoadjuvant paclitaxel plus carboplatin (TC) chemotherapy for triple-negative breast cancer. During subsequent risk-reducing salpingo-oophorectomy, a 5.5-mm nodule was observed at the edge of the left fimbria. Microscopic examination of the tumour tissue revealed high-grade serous carcinoma with degenerate tumour cells and fibrosis. Peritoneal fluid was negative for cancer cells. Two months later, hysterectomy, omentectomy and retroperitoneal lymphadenectomy were performed. The final diagnosis was stage FIGO IA fallopian tube cancer. Adjuvant chemotherapy (TC administered every 3 weeks) was applied, and there has been no evidence of recurrence for 5 years. In applying gynecologic surgery and adjuvant chemotherapy, we followed the general recommendation for stage IA fallopian tube cancer. There is no standard strategy for the treatment of occult fallopian tube cancer detected after chemotherapy for BRCA1-associated triple-negative breast cancer. According to our experience in this case, we believe the clinical value of staging laparotomy in cases of a small occult BRCA1/2-associated gynecological cancer should be further investigated.
- 30 December 2020
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 51 (3) , 492-497
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report
BRCA1/2 mutation carriers are at high risk for type II ovarian, fallopian tube or peritoneal cancer. Although risk-reducing salpingo-oophorectomy plays an important role in the prevention of these BRCA1/2-associated gynecological cancers, occult ovarian, fallopian tube, or peritoneal cancer is discovered upon risk-reducing salpingo-oophorectomy in 1–4% of BRCA1/2 mutation carriers. Notably, around 30% of BRCA1/2 mutation carriers who undergo risk-reducing salpingo-oophorectomy have undergone adjuvant chemotherapy for breast cancer. We describe the discovery and treatment of occult cancer at the edge of the left fimbria in a BRCA1 mutation carrier who had, just a short time previously, undergone neoadjuvant paclitaxel plus carboplatin (TC) chemotherapy for triple-negative breast cancer. During subsequent risk-reducing salpingo-oophorectomy, a 5.5-mm nodule was observed at the edge of the left fimbria. Microscopic examination of the tumour tissue revealed high-grade serous carcinoma with degenerate tumour cells and fibrosis. Peritoneal fluid was negative for cancer cells. Two months later, hysterectomy, omentectomy and retroperitoneal lymphadenectomy were performed. The final diagnosis was stage FIGO IA fallopian tube cancer. Adjuvant chemotherapy (TC administered every 3 weeks) was applied, and there has been no evidence of recurrence for 5 years. In applying gynecologic surgery and adjuvant chemotherapy, we followed the general recommendation for stage IA fallopian tube cancer. There is no standard strategy for the treatment of occult fallopian tube cancer detected after chemotherapy for BRCA1-associated triple-negative breast cancer. According to our experience in this case, we believe the clinical value of staging laparotomy in cases of a small occult BRCA1/2-associated gynecological cancer should be further investigated.
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (6) , e103
Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan
We conducted a retrospective, multi-institutional, collaborative study to accumulate cases of neuroendocrine carcinoma of the endometrium, to clarify its clinicopathologic features, treatment, prognosis and prognostic factors to collate findings to establish future individualized treatment regimens. To our knowledge, this is the largest case study and the first study to statistically analyze the prognosis of this disease. At medical institutions participating in the Kansai Clinical Oncology Group/Intergroup, cases diagnosed at a central pathologic review as neuroendocrine carcinoma of the endometrium between 1995 and 2014 were enrolled. We retrospectively analyzed the clinicopathologic features, treatment, prognosis and prognostic factors of this disease. A total of 65 cases were registered from 18 medical institutions in Japan. Of these, 42 (64.6%) cases were diagnosed as neuroendocrine carcinoma of the endometrium based on the central pathological review and thus included in the study. Advanced International Federation of Gynecology and Obstetrics stages (stage III and IV) and pure type small cell neuroendocrine carcinoma cases had a significantly worse prognosis. Upon multivariate analysis, only histologic subtypes and surgery were significant prognostic factors. Pure type cases had a significantly worse prognosis compared to mixed type cases and complete surgery cases had a significantly better prognosis compared to cases with no or incomplete surgery. Our findings suggest that complete surgery improves the prognosis of neuroendocrine carcinoma of the endometrium. Even among cases with advanced disease stages, if complete surgery is expected to be achieved, clinicians should consider curative surgery to improve the prognosis of neuroendocrine carcinoma of the endometrium.
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (6) , e103
Open AccessClinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan
We conducted a retrospective, multi-institutional, collaborative study to accumulate cases of neuroendocrine carcinoma of the endometrium, to clarify its clinicopathologic features, treatment, prognosis and prognostic factors to collate findings to establish future individualized treatment regimens. To our knowledge, this is the largest case study and the first study to statistically analyze the prognosis of this disease. At medical institutions participating in the Kansai Clinical Oncology Group/Intergroup, cases diagnosed at a central pathologic review as neuroendocrine carcinoma of the endometrium between 1995 and 2014 were enrolled. We retrospectively analyzed the clinicopathologic features, treatment, prognosis and prognostic factors of this disease. A total of 65 cases were registered from 18 medical institutions in Japan. Of these, 42 (64.6%) cases were diagnosed as neuroendocrine carcinoma of the endometrium based on the central pathological review and thus included in the study. Advanced International Federation of Gynecology and Obstetrics stages (stage III and IV) and pure type small cell neuroendocrine carcinoma cases had a significantly worse prognosis. Upon multivariate analysis, only histologic subtypes and surgery were significant prognostic factors. Pure type cases had a significantly worse prognosis compared to mixed type cases and complete surgery cases had a significantly better prognosis compared to cases with no or incomplete surgery. Our findings suggest that complete surgery improves the prognosis of neuroendocrine carcinoma of the endometrium. Even among cases with advanced disease stages, if complete surgery is expected to be achieved, clinicians should consider curative surgery to improve the prognosis of neuroendocrine carcinoma of the endometrium.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e17075
The efficacy and safety of nedaplatin single therapy in 30 patients with platinum-resistant ovarian cancer.
E17075 Background: This study aimed to investigate the efficacy and safety of Nedaplatin single therapy for patients with platinum-resistant ovarian, tubal and primary peritoneal cancer after completing standard chemotherapy. Methods: From September 2002 to August 2016, 30 patients who were diagnosed with platinum-resistant ovarian cancer, were treated with Nedaplatin single therapy after completing all standard chemotherapy at our institution. Nedaplatin (80-100mg/m2) was adiministered intravenously on day 1 of a 28 day cycle. We retrospectively investigated the response rate, toxicities, and survival based on the use of Nedaplatin single therapy. Results: The median age was 58.5 years (23-76). The median number of prior chemotherapy regimen was 3 (1-7). The median platinum-free interval between the final use of platinum analogues and starting Nedaplatin single therapy was 9.4 months (0.9-54.9). Among 22 patients who had measurable disease, 8 (36.4%) responded partially to Nedaplatin single therapy. Seven patients (23.3%) experienced hematological toxicities of Grade 3/4. Six patients (20.0%) experienced non-hematological toxicities Grade 2. No treatment-related death occurred. The median progression-free survival was 3.2 months (0-23.3), and over all survival was 9.2 months (1.1-56.4) after treatment with Nedaplatin single therapy. Age (<70 years, p=0.017) and platinum-free interval (<6 months, p=0.013) were the prognosis factors for survival in univariate analyses. Conclusions: Nedaplatin single therapy seemed to be an effective and safe chemotherapy regimen for platinum-resistant ovarian cancer after completing standard chemotherapy.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e17075
The efficacy and safety of nedaplatin single therapy in 30 patients with platinum-resistant ovarian cancer.
E17075 Background: This study aimed to investigate the efficacy and safety of Nedaplatin single therapy for patients with platinum-resistant ovarian, tubal and primary peritoneal cancer after completing standard chemotherapy. Methods: From September 2002 to August 2016, 30 patients who were diagnosed with platinum-resistant ovarian cancer, were treated with Nedaplatin single therapy after completing all standard chemotherapy at our institution. Nedaplatin (80-100mg/m2) was adiministered intravenously on day 1 of a 28 day cycle. We retrospectively investigated the response rate, toxicities, and survival based on the use of Nedaplatin single therapy. Results: The median age was 58.5 years (23-76). The median number of prior chemotherapy regimen was 3 (1-7). The median platinum-free interval between the final use of platinum analogues and starting Nedaplatin single therapy was 9.4 months (0.9-54.9). Among 22 patients who had measurable disease, 8 (36.4%) responded partially to Nedaplatin single therapy. Seven patients (23.3%) experienced hematological toxicities of Grade 3/4. Six patients (20.0%) experienced non-hematological toxicities Grade 2. No treatment-related death occurred. The median progression-free survival was 3.2 months (0-23.3), and over all survival was 9.2 months (1.1-56.4) after treatment with Nedaplatin single therapy. Age (<70 years, p=0.017) and platinum-free interval (<6 months, p=0.013) were the prognosis factors for survival in univariate analyses. Conclusions: Nedaplatin single therapy seemed to be an effective and safe chemotherapy regimen for platinum-resistant ovarian cancer after completing standard chemotherapy.